Clinical Trial Outcome Prediction on Clinical Trials (Phase 2)
0.88ROC AUCAliper, et al.
Evaluation results
| Method | Links | |||
|---|---|---|---|---|
| Aliper, et al.N=55,653 trials, Scope of Training Data=Multimodal2025.11 | 0.88 | — | — | |
| Lo, et al.N=6344 drugs, Scope of Training Data=Trial characteristics + drug attributes2025.11 | 0.78 | — | — | |
| Feijoo, et al.N=6417 trials, Scope of Training Data=Trial characteristics + Biomedtracker data, Evaluation Category=Neuro2025.11 | 0.76 | — | — | |
| Gao, et al.N=23,519 trials, Scope of Training Data=Trial characteristics + drug attributes2025.11 | 0.74 | — | — | |
| Zheng, et al.N=17,538 trials, Scope of Training Data=Trial characteristics + drug attributes2025.11 | 0.651 | — | — | |
| Fu, et al.N=9045 trials, Scope of Training Data=Trial characteristics, some drug attributes2025.11 | 0.65 | — | — | |
| Reinisch, et al.N=20,000 trials, Scope of Training Data=Trial characteristics + Biomedtracker data2025.11 | — | 60.4 | 60 |